Wave Crashes Down On Duchenne Fail
Suvodirsen Terminated After Negative Trial
Executive Summary
Having spectacularly failed even to match Sarepta’s Exondys 51 in the restoration of dystrophin in Duchenne muscular dystrophy patients, Wave's future is dependent on soon-to-be published data on a Huntington’s disease therapy.
You may also be interested in...
Wave’s Huntington Drugs Wipe Out As Trials Run Aground
The company now turns to its next-generation Huntington drug, WVE-003.
Finance Watch: Five More Biopharma IPOs In The US Raise $624.7m
Public Company Edition: Outside the US, Zai Lab raised more in its recent Hong Kong initial public offering – $766.4m – than PMV, Prelude, Taysha, Graybug and Greenwich combined. Also, Gilead priced debt to fund its $21bn Immunomedics buy and ADC Therapeutics raised $204m.
J.P. Morgan Stockwatch: No Substitute For M&A
Stock market reaction to the first day’s news from the 38th J.P. Morgan Healthcare conference in San Francisco was negative, probably because expectations for a continuation of December’s bumper M&A bonanza were too high.